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Study design: A randomized, double-blind, placebo-controlled, crossover, multicenter trial. A 1-week
baseline period was followed by two treatment periods of 5 weeks duration with levetiracetam
increased from 500mg b.i.d. to a maximum of 1500mg b.i.d. separated by a 1-week washout period.
Objectives: The objective of the study was primarily to evaluate the efficacy of the anticonvulsant
levetiracetam in patients with spinal cord injury (SCI) at- and below-level pain and secondarily to
evaluate the effect on spasm severity.
Setting: Outpatients at two spinal cord units and a pain center.
Methods: Patients were allowed to continue their usual pain treatment at a constant dose. The
primary outcome measure was the change in median daily pain score (on a 0–10 point numeric rating
scale) from 1-week baseline period to the last week of each treatment period. Secondary outcome
measures included pain relief of at- and below-level pain, allodynia, spasms and spasticity.
Results: A total of 36 patients with SCI at- and or below-level pain were enrolled. Of these, 24 patients
completed the trial. We found no effect of levetiracetam on the primary (P¼ 0.46) or any of the
secondary outcome measures. Only two patients continued levetiracetam treatment following the trial,
and one patient was still in levetiracetam treatment at the 6-month follow-up. Levetiracetam was
generally well tolerated with no serious adverse events.
Conclusions: Levetiracetam does not relieve neuropathic pain or spasm severity following spinal cord injury.
Spinal Cord (2009) 47, 861–867; doi:10.1038/sc.2009.55; published online 9 June 2009
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Introduction
Chronic neuropathic pain is a significant problem following
spinal cord injury (SCI). Approximately 40–50% of patients
with SCI suffer from neuropathic pain, which often has a
substantial impact on their quality of life.1–6 The anti-
convulsants pregabalin and gabapentin and the tricyclic
antidepressant amitriptyline have been shown to relieve
neuropathic pain in some patients with SCI,7–10 but many
patients fail to achieve relief and continue to suffer from
pain despite treatment attempts.11,12 Neuropathic pain felt
below the level of injury, referred to as below-level pain, is a
central pain likely to have different mechanisms than
neuropathic pain felt at the level of injury.13
Levetiracetam, the S-enantiomer of a-ethyl-2-oxo-1-pyrro-
lidine acetamide, is a novel antiepileptic drug indicated as
monotherapy in the treatment of partial onset seizures with
or without secondary generalization in patients with newly
diagnosed epilepsy and as adjunctive therapy in the treat-
ment of myoclonic seizures and primary generalized tonic-
clonic seizures. Levetiracetam binds to a synaptic vesicle
protein SV2A in the brain and spinal cord and is thought to
act by inhibiting presynaptic neurotransmitter release.14–16
In animal models of peripheral neuropathic pain, levetir-
acetam has been shown to induce antinociceptive effects.17–19
In experimental human pain models, levetiracetam in-
creased pain tolerance thresholds but had no effect on
temporal pain summation.20 An open-label study and case
reports suggest efficacy of levetiracetam in postherpetic
neuralgia,21 painful polyneuropathy,22 neoplastic plexopa-
thies23 and central neuropathic pain and spasms in multiple
sclerosis.24 Levetiracetam has a favorable adverse effect
profile with no known clinically relevant pharmacokinetic
interactions.25
The present study examined the efficacy of levetiracetam
in neuropathic pain following SCI in a randomized, double-
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blind, placebo-controlled trial and furthermore evaluated its
effect on spasms and spasticity. Parts of the article has been
presented in abstract form previously.26
Methods
Patients
Patients were recruited from December 2005 to March 2008
from the two spinal cord units in Denmark and the pain
clinic at Aarhus University Hospital. The study was approved
by the local ethical committees (no. 2005-0135), the Danish
Data Protection Agency, Copenhagen, Denmark (no. 2005-
41-5546) and the Danish Medicines Agency, Copenhagen,
Denmark (no. 2612-2919). The study was registered in the
European Clinical Database (EudraCT no. 2005-003171-21)
and in the database ClinicalTrials.gov. The study was carried
out in accordance with the International Conference on
Harmonization Good Clinical Practice (GCP) guidelines and
monitored by the GCP unit of the University of Aarhus, and
all patients gave informed written consent. Patients aged
X18 years with at- and/or below-level neuropathic pain for
at least 3 months due to trauma or disease of the spinal cord
or cauda equina with a median pain intensity X4 on a 0–10
point numeric rating scale (NRS) during a 1-week baseline
period were eligible for the study. Neuropathic pain was
defined as chronic pain in an area of sensory abnormality
corresponding to the spinal cord or nerve root lesion, and
the pain should have no primary relation to movement,
inflammation or other local tissue damage. Below-level pain
was defined as neuropathic pain present more than three
dermatomes below the neurological level and at-level pain as
pain located within the dermatome at and three dermatomes
below the neurological level.27 Patients were excluded for
any of the following reasons: known concomitant cerebral
damage, pregnancy or lactation, alcohol or substance abuse,
hypersensitivity to levetiracetam or pyrrolidine derivates,
epilepsy, psychiatric disease, depression, severe liver disease
or impaired renal function. Patients taking antidepressants
were slowly tapered off during a prestudy period of at least
1 week before the baseline period. Concomitant treatment
with spasmolytics (baclofen and tizanidine), gabapentin,
pregabalin, opioids and simple analgesics (nonsteroid anti-
inflammatory drugs, paracetamol or acetylsalicylic acid) for
pain was allowed in a constant and unchanged dose during
the trial.
Study design
The study was designed as a randomized, double-blind,
placebo-controlled, crossover, multicenter trial. The study
was carried out at the Danish Pain Research Center,
University of Aarhus, the Spinal Cord Unit, Viborg Hospital,
and the Clinic for Spinal Cord Injuries, the Neuroscience
Centre, Rigshospitalet, Denmark. At the baseline visit, a
medical history and a full neurological and physical
examination were obtained. Pain patients completed the
Danish version of the McGill pain questionnaire.28,29 Spinal
lesions were classified according to the International Stan-
dards for Neurological Classification of Spinal Cord Injury.30
A 1-week baseline period was followed by two 5-week
treatment periods with levetiracetam or identical placebo
tablets, separated by a 1-week washout period. Tablets
containing 500mg were administered as two divided doses.
The dose was gradually increased from 500mg2 in the first
week to 1000mg2 in the second week and 1500mg2 in
weeks 3–5. Patients were permitted to reduce the final dose
to 2000 or 2500mg daily if they experienced unacceptable
adverse events, but the final dose had to be at least 2000mg
and continued for at least 2 weeks to complete the trial. In
this case, the last observation carried forward was used.
Three further visits were scheduled: at the end of the baseline
week and at the end of each treatment period. Drug
compliance was monitored by counting unused tablets.
After the end of the trial, the patients were offered to start
levetiracetam treatment and all patients were sent a small
questionnaire for 6-month follow-up. The questionnaire was
returned to a research nurse, who was not involved in the
study, and sent to the primary investigator after completion
of the enrollment. Paracetamol up to 6 tablets of 500mg
daily was used as escape medication.
Assignment to treatment sequence was randomized by a
computer-generated randomization list with a block size of 4
and a consecutive allocation of patients as they entered the
study in each of the three centers. A pharmacist in the
hospital pharmacy who did not participate in conduct of
the trial generated the randomization plan. The three
investigators were provided with sealed code envelopes,
one for each patient, containing information on the
treatment given, and the envelopes were returned unopened
to the monitor after study termination.
Outcome measures
Patients were asked to rate their pain in the morning by
indicating the number that best described their pain on
average in the last 24h from 0 (no pain) to 10 (worst
imaginable pain) and sleep interference from 0 (no inter-
ference) to 10 (worst imaginable interference) using a pain
diary. The predefined primary outcome measure was the
change in median daily pain score from the baseline week to
the last week of treatment. The predefined secondary
outcome measures were the following: (1) pain relief for
overall, at-level and below-level pain (complete, good,
moderate, slight, none or worse); (2) number of patients
with 33% pain relief; (3) sleep interference; (4) use of escape
medication; (5) change in specific pain symptoms evaluated
using the Neuropathic Pain Symptom Inventory;31 (6) effect
on evoked pain: brush-evoked allodynia (pain) or dysesthesia
(unpleasantness), cold allodynia or dysesthesia (evoked by a
thermal roll of 20 1C and an acetone droplet) and pinprick
hyperalgesia (evoked by bending a von Frey hair no. 5.88,
bending force 75.9 g per 745mN, Semmes-Weinstein mono-
filaments; Stoelting, Wood Dale, IL, USA) measured on the
NRS (0–10); (7) patient global impression of change;
(8) comparison of number of responders in the group with
and without allodynia and (9) spasm intensity and severity
assessed by the patient using the NRS (0–10) and the Penn
Spasm Frequency Scale,32 and spasticity assessed by the
investigator using the modified Ashworth scale over knee
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joints.33 The baseline physical examination was carried out
by one of five experienced physicians who also (in addition
to one study nurse) performed the evaluations of pain
outcome measures, which were carried out using the same
equipment and standardized instructions to the patients.
All personnel involved were trained by the same investi-
gator (NBF).
Other measurements
Adverse events were assessed using open-ended questions at
each visit, and blindness was assessed by asking the patients
and treating researchers which treatment sequence they
believed they received and the reason for this.
Statistics
Differences in baseline data between the study population
and withdrawn patients were tested using t-test or Fisher’s
exact test. Analyses were made on patients who achieved at
least 2000mg per day levetiracetam or the corresponding
placebo for at least 2 weeks in each period (study population)
and with a compliance of tablet counts of at least 70%. For
the pain intensity scoring in the pain diary, the last
observation carried forward method was used to account
for early discontinuation; other missing data were not
replaced. A responder was defined as a patient with a 33%
pain reduction (from median daily pain during the baseline
week to the median daily pain during the last week of
treatment). Differences in treatment effect between patients
with or without concomitant pain treatment was evaluated
with Mann–Whitney U-test. Differences between treatments
were evaluated by Kock’s adaptation of the Wilcoxon signed-
rank test and the Mainland–Gart test for dichotomized data.
All P-values given are two tailed. Po0.05 was considered
statistically significant. Considering a between-treatment
group difference in pain score of at least 1.5 on the 0–10
NRS as clinically relevant and a standard deviation of 2.5,34
30 patients were expected to be sufficient to obtain
a statistical power greater than 90% (a¼0.05). With a
sample size of 24, the power of the study was 85% to detect
a 1.5-point difference.
Results
Patients
A total of 38 patients were screened and 36 randomized in the
study. Of these, 2 patients dropped out before randomization
because they could not be tapered out of escitalopram and
amitriptyline treatment, respectively. Also, 12 patients
dropped out after randomization (Figure 1) and 24 patients
achieved at least 2000mg per day for at least 2 weeks without
major protocol violation, and these comprise our study
population. The study population includes one patient who
took morphine and codeine for a short time in the middle of
the placebo period as the patient underwent hemorrhoidect-
omy. Clinical characteristics of the patients are summarized
in Table 1. The withdrawn patients and the study population
did not differ in these characteristics, but there was a
tendency that withdrawn patients were more often treated
with concomitant pain medications (11/12 versus 14/24,
P¼0.059, Fisher’s exact test). In the study population, 15
patients had evoked pain, 7 patients at-level, 3 below-level and
5 both at- and below-level pain. Of 12 withdrawn patients, 8
had evoked pain. The most common pain descriptors chosen
from the McGill pain questionnaire among the 24 patients
completing the trial were pricking/boring (18 patients),
shooting (15), tingling (14) and burning (11), whereas grueling
(13), agonizing (11), annoying (10) and blinding (10) were the
most common affective descriptors.
Of the study population, four patients discontinued
treatment early; three patients completed only 4 weeks of
levetiracetam treatment and one patient completed 4 weeks
of placebo treatment (P¼1.0, Mainland–Gart test). During
levetiracetam treatment, 21 patients reached the maximum
dosage and 3 patients received 2000mg per day, whereas 23
patients received the maximum dose during placebo treat-
ment (P¼1.0, Mainland–Gart test).
Assessed for
eligibility (n=38)
Randomized (n=36)
Received levetiracetam
(n=18)
Received
placebo (n=18)
Received placebo
(n=14)
Received levetiracetam
(n=16)
Analyzed (n=13) Analyzed (n=11)
Study population (n=24)
Withdrawn (n=4)
Adverse effects (n=3)
Protocol violation (n=1)
Withdrawn (n=2)
Adverse effects (n=1)
Increased pain (n=1)
Withdrawn (n=5)
Adverse effects (n=4)
Accident with fracture(n=1)
Withdrawn (n=1)
Adverse effects (n=1)
Could not stop current
antidepressant treatment (n=2)
Figure 1 Study flow diagram.
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Compliance
The mean compliance by tablet count was 97.7% (s.d. 7.2) in
the levetiracetam period and 97.9% (s.d. 4.4) in the placebo
period.
Primary outcome measure
There was no difference in the median pain intensity
during levetiracetam and placebo treatment (P¼0.46,
Kock’s adaptation of the Wilcoxon signed-rank test) (Table 2,
Figure 2).
Secondary outcome measures
Levetiracetam did not significantly change any of the
secondary end-points (Table 2, Figure 3). Of 20 patients, 3
during levetiracetam and 1 during placebo reported at least
moderate pain relief of their below-level pain whereas these
figures were 2 during levetiracetam and 1 during placebo of
13 patients with at-level pain. One patient in each treatment
phase obtained 50% pain relief whereas three in levetirace-
tam and four in placebo treatment obtained 33% pain relief
(responders, nonsignificant differences). Two of the three
responders to levetiracetam also reported pain relief, but
neither wished to continue treatment due to side effects,
although one later tried levetiracetam in a lower dose
without success. Of the three responders, two had evoked
pain, one with slight mechanical and cold allodynia, which
was not consistently relieved by levetiracetam, and one with
acetone-evoked dysesthesia, which was completely relieved
by levetiracetam. Two patients wished to start levetiracetam
treatment following the end of the study: one of these
because of pain relief and slight side effects in one period,
which turned out to be the placebo period. The other
patient felt an increase in pain following termination of the
study drug (levetiracetam) in period one, although no
pain relief was reported at visit 3. The first patient still
reported pain relief from levetiracetam after 6 months,
whereas the second patient terminated treatment after 2
months due to tiredness. There was no difference in pain
reduction during levetiracetam treatment between patients
treated with concomitant pain medication (n¼14) and
patients without concomitant pain medication (n¼10)
(P¼0.55, Mann–Whitney U-test) or between patients treated
with gabapentin and/or pregabalin (n¼9) and patients
without gabapentin/pregabalin treatment (n¼15) (P¼ 0.95,
Mann–Whitney U-test).
Adverse events
Seven patients were withdrawn because of side effects during
levetiracetam treatment and two during placebo treatment
(P¼0.21, Mainland–Gart test). The adverse events causing
patients to withdraw from the study during levetiracetam
treatment were incoordination (4), dizziness (3), somnolence
(3), constipation/nausea (3), confusion (1) and rash (1).
Adverse events and the number of patients reporting adverse
events and moderate to severe adverse events tended to be
more common during levetiracetam than placebo treatment,
but this was not statistically significant (P40.075, Main-
land–Gart test) (Table 3).
Assessment of blindness
Ten patients (42%) correctly identified the treatment
sequence, one identified the wrong sequence and thirteen
were unable to suggest a specific sequence (54%). The
researchers correctly identified the treatment sequence
in eight patients and identified the wrong sequence in
one. Among the 10 patients who identified the right
sequence, the reason for choosing that was pain relief in 2
patients, adverse events in 6 and both pain relief and adverse
events in 1.
Table 1 Clinical characteristics of the intention to treat and study
population
Randomized
participants
Study
population
Number 36 24
Age (years, mean (s.d.)) 52.8 (11.0) 51 (11.2)
Gender (men/women) 29/7 21/3
Mechanism of spinal injury
Transport 9 7
Fall 10 6
Sports 1 1
Transversal myelitis 6 3
Hemorrhage 2 2
Prolapsed disk/stenosis 5 4
Tumor 1 1
Operation 2 0
Neurological level
Cervical 13 10
Thoracic 19 12
Lumbosacral 4 2
AIS
A 13 10
B 2 0
C 3 2
D 18 12
Location of pain
At-level paina 17 13
Below-level paina 31 20
Treatment
Spasmolytics 15 9
Pain treatment 25 14
Gabapentin 9 4
Pregabalin 9 6
Opioids, tramadol 13 8
Simple analgesics, NSAIDs 10 5
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.
Neurological level: the most caudal segment of the spinal cord with normal
sensory and motor function on both sides of the body. AIS: American Spinal
Injury Association (ASIA) Impairment Scale: A, complete. No sensory or motor
function is preserved in the sacral segments S4-S5; B, incomplete. Sensory but
no motor function is preserved below the neurological level and includes the
sacral segments S4-S5; C, incomplete. Motor function is preserved below the
neurological level and more than half of key muscles below the neurological
level have a muscle grade less than 3; D, incomplete. Motor function is
preserved below the neurological level and at least half of key muscles below
the neurological level have a muscle grade greater or equal to 3.
aBelow-level pain extending to the at-level area is classified as below-level pain
if the patient is unable to distinguish two separate pain problems.
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Withdrawn patients
Twelve patients were withdrawn from the study, of these ten
were exposed to levetiracetam. Only one patient exposed to
levetiracetam reported pain relief but dropped out due to
side effects.
Discussion
This randomized, placebo-controlled, crossover trial of the
new anticonvulsant drug levetiracetam found no effect on
neuropathic pain following SCI. There was also no effect on
evoked pain and spasms.
Although we did not reach the predefined 30 completed
patients, the study had an adequate sample size to give an
85% power to detect a change in pain score of 1.5 point on
the NRS (0–10). There was no tendency toward treatment
effect, and the study is unlikely to have overlooked a
clinically relevant pain-relieving effect. The power calcula-
tion was carried out for the primary outcome measure and
the study may have been underpowered for other measures,
Table 2 Primary and secondary outcome measures (median (range)) at baseline, after levetiracetam and after placebo treatment
Assessment Baseline Levetiracetam Placebo
Pain intensity (NRS 0–10) 6 (4–9) 6 (3–9.5) 7 (3–9)
Categorical pain relief (worse/none/slight/moderate/good/complete) 3/18/0/2/1/0 2/20/1/0/1/0
Sleep interference (NRS 0–10) 4 (0–8) 3 (0–9) 3.5 (0–9)
Paracetamol (tablets per week) 0 (0–56) 0 (0–56) 0 (0–56)
NPSI
Burning NRS 6 (0–9) 6 (0–10) 7 (0–9)
Pressing 3.3 (0–7) 2.25 (0–7) 1.8 (0–6)
Paroxysmal 0 (0–9) 0 (0–5) 0 (0–8.5)
Evoked pain 2.3 (0–8.7) 3 (0–8.3) 2.8 (0–8.7)
Paresthesia 5 (0–10) 5 (0–10) 5 (0–10)
Evoked pain
Brush-evoked allodynia 0 (0–9) 0 (0–8) 0 (0–9)
Cold-evoked pain 0 (0–8) 0 (0–10) 0 (0–10)
Pinprick-evoked pain 0 (0–8) 0 (0–8) 1 (0–7)
Spasticity/spasms
Spasm intensity (NRS 0–10) 2 (0–8) 2 (0–8) 2 (0–8)
Penn spasm frequency 1 (0–4) 1 (0–4) 1 (0–3)
Modified Ashworth scale
Extensor 1 (0–4) 1 (0–4) 0 (0–4)
Flexor 0.5 (0–3) 0 (0–3) 0 (0–3)
Abbreviations: NPSI, neuropathic pain symptom inventory; NRS, numeric rating scale.
Pain intensity (primary outcome measure) and sleep interference are presented for the last week of each period, paracetamol as the average weekly intake and the
other measurements were evaluated at visits at the end of each period. There were no statistically significant differences between the two treatment periods in any
of the measures.
Figure 2 Pain intensity scores at baseline (gray box) and each week
during levetiracetam (diagonal lines) and placebo treatment (white
boxes). Boxes represent medians with 25th and 75th percentiles;
error bars, 10th and 90th percentiles.
Figure 3 Patient global impression of change. Number of patients
reporting a lot, some, slight, no change or worsening.
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including evoked pain and spasms, that were not present in
all patients. There was however no tendency toward
improvement in any of the secondary outcome measures.
42% identified the correct treatment sequence but this
unblinding did not result in better treatment response. The
results are in line with a recently published randomized
controlled trial, which found no effect of levetiracetam on
the postmastectomy pain syndrome.35 Most patients reached
the 3000mg per day dose, which is the maximum recom-
mended dose in epilepsy, but we cannot exclude that 5 weeks
are too short a period to test if there is a long-term effect of
levetiracetam. Levetiracetam was given as add-on to other
pain treatment in 58% of the patients. There is therefore a
risk that the study includes patients who are refractory to
further treatment effect. However, patients with and without
concomitant pain treatment had the same pain reduction
during levetiracetam treatment. In addition, although not
systematically recorded, the patients were likely to have tried
other medications without effect in tolerable doses before
entering this trial, which increases the risk of including
patients refractory to treatment.
The reason for the lack of efficacy with levetiracetam is
unknown. In animal models, levetiracetam has been shown
to induce antihyperalgesic effects in the chronic constriction
injury model17 and streptozocin-induced diabetic rats.17–19
It is possible that the pharmacological action of levetirace-
tam does not interfere with central pain mechanisms. This is
in accordance with the experimental study finding no effect
of levetiracetam on temporal pain summation.20 However,
the lack of efficacy on the postmastectomy syndrome35
suggests lack of interference with mechanisms underlying
peripheral postsurgical neuropathic pain as well. It is
possible that the pharmacological action of levetiracetam is
not involved in neuropathic pain mechanisms and that
interference with the SV2A, in levetiracetam doses used in
humans, will have no impact on neuropathic pain. However,
if levetiracetam is effective in painful diabetic neuropathy,
which has not been studied, it would suggest differences in
underlying pain mechanisms between these various neuro-
pathic pain states. A possible limitation of this study is the
heterogeneity of the group, which included patients with
both at- and below-level pain.
The high number of patients with concomitant medica-
tion may also increase the risk of additive side effect, which
is supported by the tendency toward more withdrawals
among patients with concomitant pain treatment. The study
had a remarkably low placebo effect. In general, crossover
studies have lower placebo responses than parallel group
trials.36 Interestingly, previous studies in SCI pain have
found low8 or no9,34 overall placebo response, but the reason
for this is unknown.
Central nervous system-related side effects are common
with most anticonvulsants, although the newer generation
anticonvulsants, such as levetiracetam, generally have better
safety profiles and more favorable pharmacokinetic profiles
than older generation anticonvulsants. There was a tendency
toward higher incidences of somnolence, dizziness and
incoordination as well as withdrawal due to side effects
during levetiracetam treatment than during placebo treat-
ment although there were no statistically significant differ-
ences in this relatively small study. We also saw a tendency
toward more patients reporting worsening on the patient
global impression of change scale during the levetiracetam
than the placebo period. This study suggests that levetir-
acetam may be poor tolerated in a subgroup of patients.
In conclusion, levetiracetam in doses titrated up to
3000mg had no analgesic or other benefit in patients with
neuropathic pain following SCI.
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